Capricor Therapeutics (CAPR) vs Bright Minds Biosciences (DRUG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Capricor Therapeutics (CAPR) has outperformed Bright Minds Biosciences (DRUG) over the past year, gaining 7.1% versus a loss of 5.8%. Over five years, CAPR leads with a +102.3% price change compared with +40.0% for DRUG. Bright Minds Biosciences is the larger company by market cap ($541.9 million vs $450.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAPR | DRUG |
|---|---|---|
| Share price | $7.74 | $54.94 |
| Market cap | $450.00M | $541.93M |
| 1-day change | -3.37% | +5.65% |
| YTD return | -72.25% | -33.37% |
| 1-year return | +7.09% | -5.80% |
| 5-year return | +102.27% | +39.97% |
| EPS (TTM) | $-2.45 | $-2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.37 | $123.75 |
| 52-week low | $2.96 | $47.23 |
| Distance from 52-week high | -80.83% | -55.60% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +248.84% | +176.61% |
| Average volume | 6.87M | 159.01K |
| Shares outstanding | 58.14M | 9.86M |
| Employees | 231 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAPR has outperformed DRUG by 12.9 percentage points over the past year.
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
CAPR vs DRUG FAQ
Which is bigger, Capricor Therapeutics or Bright Minds Biosciences?
Bright Minds Biosciences (DRUG) is larger, with a market capitalization of $541.93M compared with $450.00M for Capricor Therapeutics (CAPR).
Which stock has performed better over the past year, CAPR or DRUG?
CAPR returned +7.09% over the past 12 months, compared with -5.80% for DRUG (price return, excluding dividends). Past performance does not predict future results.
Are Capricor Therapeutics and Bright Minds Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.